Antarctic sea creature toxins show promise for melanoma treatment

Professor of Chemistry Brian Baker stated that toxins produced by ascidians for self-protection can be repurposed. Preliminary research has demonstrated that these toxins successfully killed melanoma cells in mice without causing harm to the animals. This finding suggests the toxins possess the necessary properties to function as a drug.

The pathway to developing a human-approved melanoma drug is extensive, involving multiple regulated trials. However, Baker believes the knowledge gained from the Antarctic expedition could accelerate this process. The expedition involved divers descending to depths of up to 130 feet for approximately 30 minutes at a time, facing challenges such as icy waters, leopard seals, and limited visibility.

Laboratory work is now underway in collaboration with the Desert Research Institute and the Scripps Institution of Oceanography to further develop the toxins. The researchers aim to understand the ecological relationship between the melanoma-killing bacterium and the microorganism it inhabits. This understanding is crucial for advancing the development of the potential drug.

Baker noted the difficulty in obtaining sufficient quantities of the metabolite from natural sources, emphasizing the need for synthetic reproduction in the lab to avoid ecological damage. He highlighted that many FDA-approved drugs originate from natural sources and described this melanoma discovery as a significant achievement in his career.